The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …

Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited
understanding of brain metastasis tumor and immune biology, drivers of resistance to …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Purpose: Central nervous system metastases are a prominent cause of morbidity and
mortality in patients with ALK-positive (ALK+) non–small cell lung cancer (NSCLC). The …

Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …

The high prices of new anticancer drugs and the marginal added benefit perceived by some
stakeholders have fuelled a debate on the value of anticancer drugs in the European Union …

Leptomeningeal metastasis (LM) is a rare complication of non-small cell lung cancer
(NSCLC) with highly mortality. LM will occur once tumor cells spread to the cerebrospinal …

Simple Summary Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
(NSCLC) was first reported in 2007. Following the development of crizotinib as a tyrosine …